Portola Pharma (PTLA) Updates on Cerdulatinib Phase 1/2a in Hematologic Cancers; Maximum Dosage Not Yet Achieved
Tweet Send to a Friend
Portola Pharma (NASDAQ: PTLA) announced updated positive safety and efficacy data from the Phase 1 part of its ongoing Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
